pocketful logo
Panacea Biotec Ltd logo

Panacea Biotec Ltd

NSE: PANACEABIO BSE: 531349

₹347.55

(-1.75%)

Thu, 12 Mar 2026, 11:25 pm

mtf coin illustrationMTF 5x

Panacea Biotec Share Price Live Chart

1 Day

0 (0%)

No Result Found

Summary

  • Market Cap

    2130.61

  • Net Profit

    -8.72

  • P/B

    3.32

  • Sector P/E

    32.85

  • P/E

    0

  • EV/EBITDA

    84.80

  • Debt/Equity (Industry)

    0.28

  • Interest Cover (Industry)

    4.55

  • ROCE (Industry)

    8.79

  • RONW (Industry)

    6.83

  • ROE

    -5.13

  • ROCE

    -4.31

  • Debt/Equity

    0.02

  • EPS (TTM)

    0

  • Dividend Yield

    0

  • Book Value

    134.92

  • Interest Cover

    -10.08

Analysis

all

thumbs up icon

Pros

  • Panacea Biotec is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Panacea Biotec is profitable, therefore cash runway is not a concern.
  • Panacea Biotec is profitable, therefore cash runway is not a concern.
  • The average tenure for the Panacea Biotec board of directors is over 10 years, this suggests they are a seasoned and experienced board.
  • Sandeep's remuneration is lower than average for companies of similar size in India.
thumbs up icon

Cons

  • Unable to calculate sustainability of dividends as Panacea Biotec has not reported any payouts.
  • Unable to evaluate Panacea Biotec's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Panacea Biotec's dividend against the top 25% market benchmark as the company has not reported any payouts.
  • Operating cash flow is negative therefore debt is not well covered.
  • Debt is not covered by short term assets, assets are 0.8x debt.

Read More

Financials

Read More

Ratios

Read More

Shareholding

ShareholdersDEC 2025SEPT 2025JUN 2025MAR 2025DEC 2024
Promoters72.4872.4872.4872.4872.49
FII1.361.060.781.160.38
DII1.851.811.521.491.17
Public24.3024.6625.2224.8625.97
Government00000

Read More

Technical Analysis

RSI

47.75

MACD

-6.68

50 DMA

362.77

200 DMA

400.99

Support and Resistance

TypeR3R2R1PPS1S2S3
Classic457.85402.50366.75347.15311.40291.80236.45
Fibonacci402.50381.36368.29347.15326.01312.94291.80
Camarilla346.22341.15336.07347.15325.93320.85315.78

Pivots Level: Classic

R3

+110.70

457.85

R2

+55.35

402.50

R1

+19.60

366.75

347.15
347.15
Pivot Point
LTP: 341.55

S1

-35.75

311.40

S2

-55.35

291.80

S3

-110.70

236.45

Moving Average

SMAEMA

Period

Value

  • 10-EMA

    338.30

  • 20-EMA

    342.19

  • 30-EMA

    347.26

  • 50-EMA

    355.55

  • 100-EMA

    371.15

  • 200-EMA

    383.01

Read More

Corporate Actions

Announcement DatePurposeActionEx Date
11 Feb 2026board-meetingsQuarterly Results
14 Nov 2025board-meetingsQuarterly Results
15 Sept 2025agm
17 Sept 2024agm
19 Aug 2024agmAnnual General Meeting20 Sept 2024
21 Aug 2023agmAnnual General Meeting22 Sept 2023
14 Aug 2023agm
19 Aug 2022agmAnnual General Meeting21 Sept 2022
09 Aug 2022agm
01 Feb 2022egm

Read More

Peer Comparison

Panacea Biotec Ltd logo

Panacea Biotec Ltd

Sun Pharmaceutical Industries Ltd logo

Sun Pharmaceutical Industries Ltd

Dr Reddys Laboratories Ltd logo

Dr Reddys Laboratories Ltd

Torrent Pharmaceuticals Ltd logo

Torrent Pharmaceuticals Ltd

Divis Laboratories Ltd logo

Divis Laboratories Ltd

Cipla Ltd logo

Cipla Ltd

Read More

Panacea Biotec Ltd About

Panacea Biotec is one of India’s leading research-based biotechnology companies engaged in the business of research, development, manufacture and marketing of vaccines in India and international markets.

Industry

Pharmaceuticals - Indian - Bulk Drugs & Formln

Founded

1984

Headquarters

CEO

Rajesh Jain

Employees

Contact

Website icon

Website

http://www.panaceabiotec.com

Email icon

Email

corporate@panaceabiotec.com; investorgrievances@pa

Phone icon

Phone

91-1762-505900

Location icon

Location

Ambala-Chandigarh Highway, , Lalru, Punjab, 140501

Read More

Panacea Biotec Ltd Company History

YearHistory
2019
  • Panacea Biotec launched ViLACT for treatment of uncontrolled Type 2 Diabetes Mellitus patients
  • Panacea Biotec received a USD 24.32 Million Award of Pentavalent Vaccine from U.N. Agencies
2021
  • RDIF and Panacea Biotec launched the production of Sputnik V in India
  • Panacea Biotec supplied the first shipment of the second component of Sputnik V vaccine produced in India
2022
  • Panacea Biotec received UNICEF and PAHO awards for supply of Pentavalent Vaccine
  • CEPI, THSTI and Panacea Biotec partnered to develop broadly protective Betacoronavirus vaccines
2023
  • Panacea Biotec launched EasyFourPol in India
  • Panacea Biotec received registration of Valganciclovir Powder for Oral Solution in Germany
  • Panacea Biotec launched Paclitaxel Protein-Bound Particles for Injectable Suspension (Albumin-Bound), a generic version of Abraxane
  • Panacea Biotec's wholly owned subsidiary launched a new range of high-quality pediatric food and nutritional products in India
2024
  • The Company received a Letter of Award from UNICEF for supply of 115 million doses of its bivalent oral polio vaccine (bOPV) worth US$ 14.95 million.

Read More

Deals

Client NameOrder SideQTYAvg PriceDate
JUNOMONETA FINSOL PRIVATE LIMITEDSell406499409.8309 Jan 2026
JUNOMONETA FINSOL PRIVATE LIMITEDBuy406451409.6509 Jan 2026
JUNOMONETA FINSOL PRIVATE LIMITEDSell450854419.5908 Jan 2026
QICAP MARKETS LLPSell444600423.8608 Jan 2026
NK SECURITIES RESEARCH PRIVATE LIMITEDBuy438702420.4808 Jan 2026
NK SECURITIES RESEARCH PRIVATE LIMITEDSell438702420.6908 Jan 2026
HRTI PRIVATE LIMITEDBuy494234417.4708 Jan 2026
QICAP MARKETS LLPBuy444600423.6108 Jan 2026
IRAGE BROKING SERVICES LLPSell234602423.6808 Jan 2026
HRTI PRIVATE LIMITEDSell455638415.8508 Jan 2026

Read More

Panacea Biotec Ltd News

Panacea Biotec subsidiary gets tax relief

Panacea Biotec's subsidiary PBPL receives favorable order reducing tax demand from ₹1.58 crore to ₹0.81 crore from Maharashtra tax authorities, company plans further appeal.

11 Mar 2026

stocks

Panacea Biotec Wins Tax Appeal, ₹329.49 Crore Demand Deleted

ITAT dismisses DCIT appeals and allows Company appeals for Assessment Years 2005-06 to 2012-13, resulting in deletion of ₹329.49 Crore tax demand and nullifying substantial contingent liabilities.

10 Mar 2026

stocks

Panacea Biotec Gets ₹10.23 Crore IT Demand Order

Panacea Biotec received income tax demand of ₹10.23 crore for AY 2016-17 due to expense disallowances. Company plans legal recourse, expects no significant impact on operations.

06 Mar 2026

stocks

Panacea Biotec Receives ₹45.71 Crore IT Demand Order

Panacea Biotec received income tax demand order of ₹45.71 crore for Assessment Year 2015-16 due to disallowed deductions under Section 37. Company plans legal recourse including rectification application.

02 Mar 2026

stocks

Panacea Biotec Q3 FY26 Results Show Mixed Performance

Panacea Biotec reported Q3 FY26 results with standalone revenue of ₹9,931 lakh and net loss of ₹736 lakh. Consolidated operations showed revenue of ₹16,519 lakh with net profit of ₹389 lakh.

12 Feb 2026

co actions results

Read More

Open Your Free Demat Account Now!

Step into a world of zero fees and limitless opportunities!

pocketful logo

2022-25 Pocketful. All rights reserved, Built with in India

Version -5.76

app image 1app image 2

Stocks:

AllABCDEFGHIJKLMNOPQRSTUVWXYZ

Explore

Calculatorsfooter arrow down icon
Popular Calculatorsfooter arrow down icon
Group Stocksfooter arrow down icon

Others:

NSEBSECDSLNSDLSEBIMCXMSEINCDEXNSE IFSCINDIA INXAccount Closure FormDP Investor CharterBroker Investor Charter

Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800